세계의 정맥혈전 색전증 시장 보고서(2025년)
Venous Thromboembolism Global Market Report 2025
상품코드 : 1825577
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ₩ 6,661,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ₩ 9,629,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ₩ 12,596,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

정맥혈전 색전증 시장 규모는 향후 수년간 안정된 성장이 전망됩니다. 2029년에는 CAGR 4.4%로 30억 2,000만 달러로 성장합니다. 예측 기간의 성장은 세계 헬스케어 접근성, 유전적 위험 평가, 원격의료 및 원격 모니터링, 환자 교육 및 지원 등에 기인하는 것으로 보입니다. 예측 기간의 주요 동향으로는 혈전 예방 확대, 신규 경구용 항응고제, 개인별 맞춤 치료 계획, 첨단 영상 진단 등이 있습니다.

향후 5년간 성장률 4.4%라는 예측은 지난번 예측보다 0.1% 소폭 하락한 수치입니다. 이 감소는 주로 미국과 다른 국가 간의 관세의 영향에 기인합니다. 관세 인상은 아일랜드와 벨기에에서 직접 조달하는 경구용 항응고제 및 기계식 혈전 제거 장치의 비용을 상승시켜 치료 비용을 악화시키고 생명을 구하는 치료를 지연시킴으로써 미국 병원에 부담을 줄 가능성이 높습니다. 또한 상호 관세와 무역 긴장과 제한 증가로 인한 세계 경제와 무역에 대한 악영향으로 인해 그 영향은 더욱 광범위하게 나타날 것으로 보입니다.

헬스케어 인프라의 확대는 정맥혈전색전증(VTE) 시장의 성장을 가속할 것으로 예측됩니다. 헬스케어 인프라는 예방, 치료, 재활 서비스를 포함한 의료 서비스를 제공할 수 있는 시스템, 제도, 정책, 자원을 말합니다. 성장하는 헬스케어 산업은 VTE 예방 프로토콜의 시행과 관련 치료법 개발을 지원하고 있습니다. 예를 들어 2023년 5월 미국 의료 협회는 미국 병원 수가 2022년 6,093개에서 2023년 6,129개로 증가했다고 보고했습니다. 마찬가지로 영국 통계청은 2023년 의료비 지출이 5.6% 증가하여 2,920억 파운드에 달할 것이라고 보고했습니다. 또한 장기적으로 의료 및 사회보장 지출은 2022년 실질 기준으로 2.8% 증가했습니다. 의료 시스템이 확장됨에 따라 VTE 예방에 점점 더 많은 초점을 맞추고 있으며, 그 결과 관련 제품 및 서비스 시장이 활성화되고 있습니다.

목차

제1장 개요

제2장 시장의 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세 및 Covid와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별·국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

제31장 기타 대기업과 혁신적 기업

제32장 세계의 시장 경쟁 벤치마킹과 대시보드

제33장 주요 합병과 인수

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

KSA
영문 목차

영문목차

Venous thromboembolism (VTE) is a medical condition marked by the development of blood clots within the veins, carrying the potential for serious or life-threatening complications. Common indicators of VTE encompass symptoms like leg pain and swelling, rapid breathing, chest discomfort, and more. Diverse treatment methods, including anticoagulant medications, medical devices, and thrombolytic therapy, are employed in managing VTE.

The primary categories of venous thromboembolism consist of deep vein thrombosis, pulmonary embolism, and other related conditions. Deep vein thrombosis (DVT) represents a medical condition characterized by the development of blood clots within the deep veins of the body. Treatment options encompass the use of anticoagulant medications, mechanical devices, thrombolytic therapy, and various other interventions. These treatments cater to diverse end-users, including hospitals, homecare settings, specialty centers, and other relevant healthcare facilities.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The venous thromboembolism market research report is one of a series of new reports from The Business Research Company that provides venous thromboembolism market statistics, including venous thromboembolism industry global market size, regional shares, competitors with a venous thromboembolism market share, detailed venous thromboembolism market segments, market trends and opportunities and any further data you may need to thrive in the venous thromboembolism industry. This venous thromboembolism market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The venous thromboembolism market size has grown steadily in recent years. It will grow from $2.44 billion in 2024 to $2.53 billion in 2025 at a compound annual growth rate (CAGR) of 3.9%. The growth in the historic period can be attributed to aging population, advancements in anticoagulants, reimbursement policies, increasing investments.

The venous thromboembolism market size is expected to see steady growth in the next few years. It will grow to $3.02 billion in 2029 at a compound annual growth rate (CAGR) of 4.4%. The growth in the forecast period can be attributed to global healthcare access, genetic risk assessment, telemedicine and remote monitoring, patient education and support. Major trends in the forecast period include extended thromboprophylaxis, novel oral anticoagulants, personalized treatment plans, advanced diagnostic imaging.

The forecast of 4.4% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff escalations are likely to burden U.S. hospitals by driving up the cost of direct oral anticoagulants and mechanical thrombectomy devices sourced from Ireland and Belgium, exacerbating treatment costs and delaying life-saving interventions. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The expansion of healthcare infrastructure is expected to drive the growth of the venous thromboembolism (VTE) market. Healthcare infrastructure refers to the systems, institutions, policies, and resources that enable the delivery of medical care, including prevention, treatment, and rehabilitation services. The growing healthcare industry supports the implementation of VTE prevention protocols and the development of related treatments. For example, in May 2023, the American Health Care Association reported an increase in the number of hospitals in the U.S., rising from 6,093 in 2022 to 6,129 in 2023. Similarly, the Office for National Statistics in the UK reported a 5.6% increase in healthcare expenditure, which reached £292 billion in 2023. Additionally, long-term health and social care expenditures rose by 2.8% in real terms in 2022. As healthcare systems expand, they will increasingly focus on VTE prevention, thus boosting the market for related products and services.

The growth of the venous thromboembolism market is further bolstered by the escalating number of orthopedic procedures. Orthopedic procedures encompass various surgical interventions used to address conditions affecting the spine, joints, and skeletal deformities. Procedures like total knee arthroplasty (TKA), total hip arthroplasty (THA), and hip fracture surgery (HFS) are associated with a heightened risk of VTE, leading to an increased adoption of compression devices for DVT prophylaxis. Compression devices serve to prevent the formation of blood clots in the deep veins of the legs, mitigating the risk of venous thromboembolism (VTE). For instance, research published by the National Library of Medicine in February 2023 indicates that THA and TKA procedures are projected to rise significantly, with 1,222,988 and 719,364 procedures, respectively, anticipated by 2040. Moreover, TKAs are estimated to reach 2,917,959 by 2060, while THAs are projected to total 1,982,099 by that time. Consequently, the mounting number of orthopedic procedures is a significant driver of the venous thromboembolism market's growth.

Leading companies within the venous thromboembolism market are spearheading the development of innovative anticoagulant drugs and solutions to maintain their market positions. Advances in anticoagulants hold the potential to yield more effective drugs capable of preventing or treating venous thromboembolism. For example, in September 2022, Anthos Therapeutics, a US-based clinical-stage biotherapeutics company, secured regulatory approval for its abelacimab anticoagulant medication from the Food and Drug Administration (FDA). This fully human monoclonal antibody is indicated for stroke and systemic embolism prevention in atrial fibrillation patients. The newly developed abelacimab, a once-monthly dual-acting antibody, is designed to provide hemostasis-sparing anticoagulation by inhibiting Factor XI.

In August 2022, Boston Scientific Corporation, a US-based leader in surface modification technologies, acquired Obsidio, Inc., a US-based company specializing in biodegradable embolic materials for treating venous conditions, for an undisclosed amount. This acquisition strengthens Boston Scientific's portfolio of innovative therapies, expanding its capabilities in minimally invasive procedures aimed at patients with venous conditions. The acquisition is expected to enhance the company's offerings in the growing field of venous health, particularly with Obsidio's cutting-edge materials designed to improve treatment outcomes for patients suffering from conditions like venous thromboembolism (VTE).

Major companies operating in the venous thromboembolism market are Pfizer Inc., Johnson and Johnson Limited, Merck and Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi-Aventis LLC., Bristol-Myers Squibb Company, GlaxoSmithKline plc., Eli Lilly and Co Ltd., Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Limited, Otsuka Pharmaceutical Co. Ltd., Menarini Group, Ipsen S.A., Dr. Reddy's Laboratories Ltd., Apotex Inc., Hikma Pharmaceuticals PLC, Cipla Inc., Endo International PLC, Aspen Pharmacare Holdings Limited, Zydus Lifesciences Ltd., LEO Pharma A/S, Lupin Limited, Torrent Pharmaceuticals Ltd., Almirall S.A., Glenmark Pharmaceuticals Ltd., Portola Pharmaceuticals Inc.

North America was the largest region in the venous thromboembolism market in 2024. The regions covered in venous thromboembolism report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the venous thromboembolism market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The venous thromboembolism market consists of revenues earned by entities by providing services such as surgical assistance and thrombolytic therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The venous thromboembolism market also includes the sales of heparin, apixaban, dabigatran, rivaroxaban, edoxaban and warfarin. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Venous Thromboembolism Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on venous thromboembolism market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for venous thromboembolism ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The venous thromboembolism market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Venous Thromboembolism Market Characteristics

3. Venous Thromboembolism Market Trends And Strategies

4. Venous Thromboembolism Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Venous Thromboembolism Growth Analysis And Strategic Analysis Framework

6. Venous Thromboembolism Market Segmentation

7. Venous Thromboembolism Market Regional And Country Analysis

8. Asia-Pacific Venous Thromboembolism Market

9. China Venous Thromboembolism Market

10. India Venous Thromboembolism Market

11. Japan Venous Thromboembolism Market

12. Australia Venous Thromboembolism Market

13. Indonesia Venous Thromboembolism Market

14. South Korea Venous Thromboembolism Market

15. Western Europe Venous Thromboembolism Market

16. UK Venous Thromboembolism Market

17. Germany Venous Thromboembolism Market

18. France Venous Thromboembolism Market

19. Italy Venous Thromboembolism Market

20. Spain Venous Thromboembolism Market

21. Eastern Europe Venous Thromboembolism Market

22. Russia Venous Thromboembolism Market

23. North America Venous Thromboembolism Market

24. USA Venous Thromboembolism Market

25. Canada Venous Thromboembolism Market

26. South America Venous Thromboembolism Market

27. Brazil Venous Thromboembolism Market

28. Middle East Venous Thromboembolism Market

29. Africa Venous Thromboembolism Market

30. Venous Thromboembolism Market Competitive Landscape And Company Profiles

31. Venous Thromboembolism Market Other Major And Innovative Companies

32. Global Venous Thromboembolism Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Venous Thromboembolism Market

34. Recent Developments In The Venous Thromboembolism Market

35. Venous Thromboembolism Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기